ACE-031 1mg
Investigational ActRIIB-Fc decoy protein evaluated for myostatin inhibition, discontinued due to vascular adverse events.
Mechanism
Acts as an ActRIIB decoy receptor that traps myostatin and activin-family ligands, preventing them from binding natural receptors to relieve the biological brake on muscle enlargement.
Dosing
Clinical protocols were terminated, though laboratory measurement references begin with a nominal 100 mcg benchmark.
Reconstitution
Reconstituting a 1 mg vial with 1.0 mL of bacteriostatic water creates an experimental concentration of 1.0 mg/mL.
Storage
Store the intact or reconstituted solution refrigerated between 2°C and 8°C protected from light, avoiding freezing or agitation to preserve protein integrity.
Mix & measure ACE-031 1mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure ACE-031 1mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 10.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Reference Baseline | 100 mcg (Laboratory Reference) | 0.10 mL (10 units) |
| Intermediate Reference | 200 mcg (Laboratory Reference) | 0.20 mL (20 units) |
| Upper Experimental Ref | 500 mcg (Laboratory Reference) | 0.50 mL (50 units) |
| Full Vial Equivalent | 1 mg (Laboratory Reference) | 1.00 mL (100 units) |
Reconstitution Steps
- 1
Clean the rubber stoppers of both the ACE-031 vial and the bacteriostatic water with sterile alcohol pads and allow to air dry.
- 2
Draw 1.0 mL of bacteriostatic water into a sterile mixing syringe.
- 3
Insert the needle at a slight angle and allow the diluent to run gently down the inside glass wall to avoid foaming.
- 4
Gently rotate or roll the vial between your palms until the lyophilized cake is fully dissolved without shaking.
- 5
Visually inspect the solution for clarity and refrigerate immediately between 2°C and 8°C.
Supplies Needed
Peptide Vial
Contains 1 mg lyophilized ACE-031 fusion protein
Insulin Syringes (U-100)
Used for precise volumetric measurement of reconstituted liquid
Bacteriostatic Water
Provides 1.0 mL of sterile diluent preserved with benzyl alcohol
Alcohol Swabs
Sanitizes vial stoppers and contact surfaces prior to mixing
Why researchers study it
Regulation of myostatin and activin signaling in skeletal muscle hypertrophy
Mechanisms behind early clinical trials for Duchenne muscular dystrophy
Effects of non-selective ligand sequestration on vascular integrity and bleeding
Historical evaluation of ActRIIB-Fc soluble decoy proteins
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
ACE-031, also known experimentally as ramatercept, represents an engineered soluble fusion protein composed of the extracellular domain of the activin receptor type IIB linked to an IgG1-Fc tail. Formulated initially to address severe degenerative muscle-wasting disorders, it serves as a circulating decoy receptor that sequesters negative growth factors such as myostatin and activins before they can bind cell-surface receptors. While early Phase 1 trials demonstrated clear increases in lean mass and thigh volume in healthy volunteers, subsequent clinical evaluation in pediatric Duchenne muscular dystrophy was terminated early due to vascular off-target manifestations, including epistaxis and telangiectasias. Because broad TGF-beta family ligand binding affects non-skeletal tissues, the therapeutic index proved unacceptable for commercial drug development. Today, ACE-031 is referenced strictly as an experimental tool in comparative myostatin pathway biology. Standard research-grade vials are produced solely for in vitro analysis or laboratory measurement conversions, carrying significant off-target warnings and no verified safety clearance for administration.
References
- 1.McPherron et al., Nature, 1997 — Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member
- 2.Cadena et al., Journal of Applied Physiology, 2010 — Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
- 3.Attie et al., Muscle & Nerve, 2013 — A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
- 4.Campbell et al., Muscle & Nerve, 2017 — Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allKPV 10mg
KPV is an alpha-MSH-derived C-terminal tripeptide studied for NF-kB suppression, mucosal healing, and inflammatory modulation.
View ProtocolVIP 5mg
A 28-amino-acid neuropeptide acting on VPAC receptors, studied for mucosal integrity, systemic inflammation, and pulmonary tissue signaling.
View ProtocolPEG-MGF 2mg
A pegylated mechano growth factor analogue investigated in preclinical models for myogenic satellite cell recruitment and tissue repair.
View Protocol